麻豆AV

Today, 听and Canada鈥檚 听are releasing initial results of the first 10,000 blood donor samples assessed for SARS-CoV-2 antibodies. This analysis reveals that over the period May 9 through June 8, 2020, fewer than 1 per cent of the 10,000 samples from blood donors tested positive for antibodies to the novel coronavirus. Antibodies indicate past infection with SARS-CoV-2, and population studies like this one tell us how many people have likely been exposed to the virus.

These results offer a first, high-level glimpse into an ongoing Canadian Blood Services study assessing SARS-CoV-2 antibodies across nine provinces. They will be updated once Canadian Blood Services completes their analysis of the full sample of 37,800 donations made during the months of May and June 2020. In addition, H茅ma-Qu茅bec will have results for Quebec in the near future, which will be important for a complete national picture, given the COVID-19 rates in that province.

While there will be adjustments to this initial figure once the full 10-province study is completed in the coming weeks, Professor Catherine Hankins, CITF Co-Chair, believes its implications bear public attention immediately, as reopening is causing a worrisome uptick in COVID-19 cases across Canada.

鈥淲hat is clear is that only a small percentage of adult Canadians has been infected by SARS-CoV-2,鈥� Hankins says. 鈥淏y far, the majority of us remain vulnerable to infection. We need to ramp up testing and tracing capacity across the country to interrupt any chains of transmission quickly to prevent unchecked spread.鈥�

CITF Co-Chair Professor David Naylor concurred: 鈥淭hese data suggest there are several undetected infections for every case confirmed with swabs and RNA tests. That lends weight to current public health advice. Please wear a mask in public indoor spaces, wash your hands often, and practice physical distancing if you鈥檙e around people who aren鈥檛 in your COVID-19 鈥榖ubble鈥�.鈥�

Acknowledging that many more adult Canadians are infected than currently documented, Professor Timothy Evans, CITF Executive Director cautioned against over-interpreting the apparent reduction in risk. 鈥淎mong adults, the death rate from being infected with SARS-CoV-2 is likely closer to one per cent, as compared to the eight per cent reported to date among those diagnosed with COVID-19. But this is a highly infective virus that could take a huge toll if we allow it to spread, and we are only now learning that many survivors have persistent symptoms.鈥�

These initial results from Canadian Blood Services and CITF are a first step toward giving policymakers a deeper understanding of the COVID-19 infection rate across Canada. As further samples are analyzed by Canadian Blood Services and H茅ma-Qu茅bec, the findings will offer new insights to help guide effective public health measures.

鈥淚 want to thank Canadians for the sacrifices made to flatten the curve in the first wave. While these first results reflect widespread adherence with public health measures, they also mean most Canadians remain susceptible to infection,鈥� says the Honourable Patty Hajdu, Minister of Health. 鈥淎s we start to see case numbers rise again, we all need to follow public health advice and avoid crowded places, close-contact settings and confined spaces.鈥�

When the Government of Canada established CITF in late April 2020, Canadian Blood Services and H茅ma-Qu茅bec reached out to offer their assistance. Canada鈥檚 blood system became the first place the initiative looked for evidence of infection and immunity in the Canadian population.

The choice was obvious. Blood donation centres are a rapid and reliable resource for generating insights into the patterns of illness, such as COVID-19, in the broader population. Canadian Blood Services and H茅ma-Qu茅bec routinely test blood donations, including tests for pathogens that can be transmitted through transfusion (SARS-CoV2 is not known to be transfusion-transmitted). Both organizations also regularly contribute to active, ethics-approved research programs like this one, some of which in the past have included seroprevalence work to guide policies.

鈥淐anadian Blood Services is proud to support the CITF鈥檚 mandate,鈥� says Dr. Graham Sher, Chief Executive Officer, Canadian Blood Services. 鈥淲e are uniquely positioned to help by providing information on the presence of COVID-19 antibodies in a large number of people across Canada relatively quickly. This is a great opportunity and privilege for blood donors and staff at Canadian Blood Services to contribute to a national need in a novel way.鈥�

鈥淕etting an early picture of the levels of population immunity is critical to inform the public health response,鈥� says Dr. Marc Germain, Vice-President, Medical Affairs and Innovation, H茅ma-Qu茅bec. 鈥淲e look forward in the coming days to sharing the results of the first study on antibodies to SARS-CoV-2 among blood donors in Quebec.鈥�

###

听

About the COVID-19 Immunity Task Force

The Government of Canada launched the COVID-19 Immunity Task Force in late April 2020 to measure the scope of coronavirus infection in Canada and rapidly provide information to manage the COVID-19 pandemic and safely get Canadians back to work. The Task Force has the mission of ensuring that at least one million Canadian blood samples are collected and tested over the next two years to track the spread of the virus in the general population and shed light on immune responses to it in a diversity of communities, settings, age brackets, and occupational groups across the nation. For more information visit:

About Canadian Blood Services

Canadian Blood Services is a not-for-profit charitable organization. Regulated by Health Canada as a biologics manufacturer and primarily funded by the provincial and territorial ministries of health, Canadian Blood Services operates with a national scope, infrastructure and governance that make it unique within Canadian healthcare. In the domain of blood, plasma, and stem cells, we provide services for patients on behalf of all provincial and territorial governments, except Quebec. The national transplant registry for interprovincial organ sharing and related programs reaches into all provinces and territories, as a biological lifeline for Canadians. For more information visit:

Media contacts

COVID-19 Immunity Task Force
Katherine Gombay
katherine.gombay [at] mcgill.ca/ info [at] covid19immunitytaskforce.ca
514-717-2289

Canadian Blood Services
media [at] blood.ca
1-877-709-7773